November 16-19, 2026 | Boston, USA
Priavoid will present topline results from its Phase 2 trial PRImus-AD, evaluating its lead candidate PRI-002 in patients with early Alzheimer’s disease, in an oral presentation at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, USA.
Presentation details
- Title: Topline results from the Phase 2b PRImus-AD trial: Safety and efficacy of oral PRI-002 in early AD
- Presentation ID: OC9
- Date: November 17, 2026
- Time: 10:05 am ET
- Presenter: Oliver Peters, CMO at Priavoid
- Location: Ballroom – 4th floor
- Venue: Boston Marriott Copley Place
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.


